Engineered Intrabodies Open New Paths in Neurodegeneration

REPURPOSING antibody fragments for intracellular targeting gives clinicians new tools against neurodegenerative disease aggregates. While traditional monoclonal antibodies excel at binding extracellular antigens, single-chain variable fragments historically aggregate and rapidly lose functionality within the reducing cytoplasmic environment. Investigators resolved this persistent therapeutic bottleneck by establishing that whole-molecule net electrical charge serves as the primary determinant of intracellular solubility. Comprehensive analysis of more than one million paired variable domains demonstrated that natural antibody fragments are substantially more electropositive than native cytoplasmic human proteins. By engineering single-chain variable fragments to carry a net negative charge below minus fifteen through specialized interdomain linkers and terminal tags, investigators achieved intracellular solubility exceeding eighty percent without compromising baseline structural integrity.

Transforming the Antibody Interactome Through Inverse Folding

To expand this redesign strategy across the broader antibody interactome, researchers paired deep-learning inverse folding algorithms with precise structural constraints. Using ProteinMPNN alongside domain orientation rules, artificial intelligence systematically re-engineered variable framework regions to reduce surface positive charge while strictly protecting critical complementarity-determining regions and interface beta-sheets. This in silico platform yielded stable, highly soluble engineered intrabodies targeting sixty distinct intracellular proteins involved in oncologic and neurodegenerative pathways. The methodology reliably preserved parent antibody specificity across hundreds of constructs, generating validated candidates for targets such as p53, tau, ubiquitin carboxy-terminal hydrolase L1, and fused in sarcoma protein.

Targeting Pathological Aggregates in Neurologic Disorders

The translational relevance of engineered intrabodies centers on their capacity to differentiate pathogenic conformations and mutant protein states within living cells. In cellular assays, engineered intrabodies selectively bound mutant superoxide dismutase 1 variants implicated in amyotrophic lateral sclerosis while completely sparing wild-type protein. In addition, engineered intrabodies exhibited robust state-specific engagement with alpha-synuclein and polyglutamine stretches associated with Parkinson’s disease and Huntington’s disease. By repurposing established clinical and research antibodies for intracellular action, this engineering blueprint provides a versatile pipeline to enhance gene therapies, guide targeted protein degradation, and neutralize intracellular disease drivers directly at the site of pathology.

Reference

O’Shea CM et al. Reliable repurposing of the antibody interactome inside the cell. Nat Commun. 2026;17:2222.

Featured Image: arcyto on Adobe Stock.